An Update on C-Kad OS Eye Drops for the Treatment of Cataracts and Other Degenerative Eye Diseases

The use of C-KAD OS Ophthalmic Solution for the treatment of cataracts is coming closer to a reality, as it undergoes Phase II clinical trials by the U.S. Food and Drug Administration.

News of this new treatment option first broke in the spring of 2008. See my previous article dated April, 2008: C-Kad OS Eye Drops: New Cure for Cataracts

The Story Behind the Cure

Researcher, skilled mathematician and alchemist, Rajiv Bhushan set out to find a cure for his father's vision loss due to cataracts. He began using his prior understanding of oxidative stress to explore every avenue to find a cure for his father's health issues and vision problems. His work and dedication led him to the discovery of combining two ingredients that were already deemed safe and after developing the right combination of these two ingredients, he treated his father and achieved some rather amazing results. Within two weeks of this treatment, his father's vision began to improve and has continued to do so for over one year. His father now lives an independent life due to the scientific efforts of his loving son.

Chakshu Research, Inc.

After observing such remarkable results in his father's eye condition, Rajiv Bhushan decided to share his discovery with Amit Goswamy. The Chakshu Research, Inc. was born and is dedicated to the treatment of degenerative ocular diseases. Clinical trials are currently underway to study the effectiveness of the self-administered eye drop treatment of cataracts, glaucoma and asteroid hyalosis.

Wikipedia definitions:

Cataract: " . . . a clouding that develops in the crystalline lens of the eye or in its envelope, varying in degree from slight to complete opacity and obstructing the passage of light."

Glaucoma: " . . . a group of diseases of the optic nerve involving loss of retinal ganglion cells in a characteristic pattern of optic neuropathy."

Ocular Asteroids: " . . . floaters, which are usually fibrillar or cellular condensates. . . . associated with diabetes mellitus, hypertension, hypercholesterolemia, and tumors of the ciliary body."

Recruitment of volunteers for these clinical trials are underway in four locations across the United States:

Pacific Eye Specialists

San Francisco, CA

Hunkeler Eye Institute

Overland Park, Kansas

Minnesota Eye Consultants, PA

Minneapolis, MN

Charlotte Eye, Ear, Nose & Throat Associates

Charlotte, North Carolina

Sponsors and Collaborators: Chakshu Research, Inc.

For more information or to participate in this study, you may contact:

Chakshu Research, Inc. Clinical & Regulatory Affairs

Study ID Numbers: CK-0109

Clinical Trials Identifier # NCT00793091

As the Baby Boomer generation continues to age, degenerative eye diseases will become more and more common. It is exciting to see the promise of this new treatment that can be self-administered in the form of eye drops. I wait, along with many others, for more news regarding these clinical trials of C-Kad OS Eye Drops.

Sources:

http://www.chakshu.com/about.html

http://clinicaltrials.gov/ct2/show/NCT00793091?term=Chakshu&rank=1

http://en.wikipedia.org/wiki/Cataract

http://en.wikipedia.org/wiki/Glaucoma

http://en.wikipedia.org/wiki/Asteroid_hyalosis